

IN THE CLAIMS:

Please enter the attached listing of claims into the application. This listing of claims replaces all prior listing of claims in the application.

LISTING OF CLAIMS

1-14. (Cancelled)

15. (Previously Presented) A method of increasing sensorimotor gating in a human subject having a bipolar disease or disorder, an anxiety disease or disorder or a depression disease or disorder associated with serotonin-2A mediated neurotransmission, the method comprising administering to the subject an NT agonist selected from the group consisting of NT69L, (Boc-Lys₉)-neurotenin(9-13)-methyl ester, (Dab₉)-neurotensin(8-13), (Dab₉)-neurotensin(9-13), (Lys₉, Trp₁₁, Glu₁₂)-neurotensin(8-13), PD149163, NT1, NT2, NT64D, NT64L, NT65L, NT66D, NT66L, NT67L, NT69L', NT71, NT72, NT73, NT74, NT75, NT76, and NT77 in an amount effective to improve symptoms of the disease or disorder relative to the human subject not treated with the NT agonist, wherein the NT agonist inhibits serotonin-2A mediated neurotransmission.

16. (Previously Presented) A method of improving symptoms in a human subject having a bipolar disease or disorder, an anxiety disease or disorder or a depression disease or disorder associated with serotonin-2A mediated neurotransmission comprising administering to the subject an NT agonist selected from the group consisting of NT69L, (Boc-Lys₉)-neurotenin(9-13)-methyl ester, (Dab₉)-neurotensin(8-13), (Dab₉)-neurotensin(9-13), (Lys₉, Trp₁₁, Glu₁₂)-neurotensin(8-13), PD149163, NT1, NT2, NT64D, NT64L, NT65L, NT66D, NT66L, NT67L, NT69L', NT71, NT72, NT73, NT74, NT75, NT76, and NT77 in combination with other psychotropic drugs, in an amount effective to improve symptoms of the disease or disorder, wherein the NT agonist inhibits serotonin-2A mediated neurotransmission.

17. (Previously Presented) The method of either claim 15 or 16, further comprising administering a compound selected from the group consisting of levocabastine, SR48692, and SR142948.
18. (Previously Presented) The method of either claim 15 or 16 wherein the NT agonist is administered by a route selected from the group consisting of parenterally, topically, subcutaneously, subdermally, and transmucosally.
- 19-21. (Cancelled)
22. (Previously Presented) The method of either claim 15 or 16 wherein the bipolar disease or disorder, the anxiety disease or disorder or the depression diseases or disorder is associated with sensorimotor gating abnormalities.
23. (Cancelled)
24. (Previously Presented) A method of inhibiting serotonin-2A and/or alpha-1 receptor mediated neural function in a human subject having a bipolar disease or disorder, an anxiety disease or disorder or a depression disease or disorder comprising administering to a subject an effective amount of an NT agonist selected from the group consisting of NT69L, (Boc-Lys₉)-neurotenin(9-13)-methyl ester, (Dab₉)-neurotensin(8-13), (Dab₉)-neurotensin(9-13), (Lys₉, Trp₁₁, Glu₁₂)-neurotensin(8-13), PD149163, NT1, NT2, NT64D, NT64L, NT65L, NT66D, NT66L, NT67L, NT69L', NT71, NT72, NT73, NT74, NT75, NT76, and NT77 wherein serotonin-2A and/or alpha 1 receptor mediated neural function is inhibited and wherein symptoms associated with the disease or disorder are reduced.

25. (Previously Presented) The method of claim 24, further comprising administering a compound selected from the group consisting of levocabastine, SR48692, and SR142948.

26. (Previously Presented) The method of claim 24, wherein the NT agonist is administered by a route selected from the group consisting of parenterally, subcutaneously, subdermally, topically, and transmucosally.

27-34. (Cancelled).